Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer - A Retrospective Analysis of the Swiss Lenvatinib Named Patient Program

Purpose:Differentiated thyroid cancer (DTC) accounts for approximately 95% of thyroid carcinomas. In the metastatic RAI-refractory disease, chemotherapy has very limited efficacy and is associated with substantial toxicity. With increasing knowledge of the molecular pathogenesis of DTC, novel target...

Descripción completa

Detalles Bibliográficos
Autores principales: Balmelli, Catharina, Railic, Nikola, Siano, Marco, Feuerlein, Kristin, Cathomas, Richard, Cristina, Valerie, Güthner, Christiane, Zimmermann, Stefan, Weidner, Sabine, Pless, Miklos, Stenner, Frank, Rothschild, Sacha I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5771331/
https://www.ncbi.nlm.nih.gov/pubmed/29344270
http://dx.doi.org/10.7150/jca.22318

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5771331/
https://www.ncbi.nlm.nih.gov/pubmed/29344270
http://dx.doi.org/10.7150/jca.22318

Ejemplares similares